提供学术论文选刊润色服务

EXPERT OPINION ON THERAPEUTIC TARGETS 期刊封面

医学

返回期刊列表

Review Cycle Records

EXPERT OPINION ON THERAPEUTIC TARGETS

Taylor & Francis SCIE 非OA

2026新锐 3区2025中科院 2区2025 JCR Q1

查看审稿周期计算与数据来源报告数据问题

97.4平均天数

89.5中位天数

39最短天数

200最长天数

742025发文量

Paper Review Records

全部论文审稿周期

10 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期；保留 PDF/DOI/网页源链接

108 天

5-FU in combination with PARP inhibitor ABT-888 deregulates MGMT-dependent mismatch repair (MMR) pathway in MMR-proficient colorectal cancer stem cells by modulating MGMT/PARP1/MSH6 complex

收稿 2026-03-29 录用 2026-07-15 发表 2026-07-23

作者Subarno Paul; Chinmay Das; Subhasmita Bhal; Saptarshi Sinha; Somya Ranjan Dash; Sushree Subhadra Acharya; Aakash Goswami; Kunal Goutam; Chanakya Nath Kundu; Tithi Parija

作者单位1. Deemed to Be University; 2. Acharya Harihar Post Graduate Institute of Cancer

PDF源文件 DOI 网页

84 天

The evolving bioinformatic approaches to identifying genetic targets of promise in cancers

收稿 2026-04-09 录用 2026-07-02 发表 2026-07-22

作者Vijay Kumar; Darin Mansor Mathkor; Shafiul Haque

作者单位1. Amity University; 2. Jazan University; 3. Universidad Espiritu Santo

PDF源文件 DOI 网页

97 天

Tailored strategies to overcome third-generation TKI resistance in EGFR-mutated non-small cell lung cancer

收稿 2026-04-09 录用 2026-07-15 发表 2026-07-22

作者Isabella Saporita; Giovanni Farinea; Elisa Lombardi; Paolo Bironzo; Silvia Novello; Francesco Passiglia

作者单位1. University of Turin, San Luigi Hospital

PDF源文件 DOI 网页

39 天

APE1/Ref-1: multifunctional biology, selective inhibition, and the path to clinical translation

收稿 2026-06-06 录用 2026-07-15 发表 2026-07-21

作者Jessica A. Occhiuto; Silpa Gampala; Melissa L. Fishel; Mark R. Kelley

作者单位1. Indiana University School of Medicine

PDF源文件 DOI 网页

70 天

Fibroblast activation protein inhibitor-based theranostics in neuroendocrine neoplasms

收稿 2026-05-06 录用 2026-07-15 发表 2026-07-20

作者Anna La Salvia; Daniela Lucente; Stefania Bellino

作者单位1. Istituto Superiore di Sanità

PDF源文件 DOI 网页

58 天

Possibility to therapeutically exploit RGPR-p117 as a target in cancer cells

收稿 2026-05-18 录用 2026-07-15 发表 2026-07-19

作者Masayoshi Yamaguchi

作者单位1. University of Hawaii Cancer Center, University of Hawaii

PDF源文件 DOI 网页

94 天

The role of bile acid receptors in cholestatic liver disease: pathophysiological insights and therapeutic advances

收稿 2026-03-22 录用 2026-06-24 发表 2026-07-04

作者Hongying Zhou; Jie Yang; Wenbin Wu; Shizhang Wei; Yanling Zhao; Chunyu Li

作者单位1. The First Affiliated Hospital of China Medical University; 2. Offices Administration of the Central Military Commission; 3. Chinese Academy of Medical Sciences and Peking Union Medical College; 4. Chinese PLA General Hospital

PDF源文件 DOI 网页

85 天

Molecular insights for targeting the Nrf1 pathway in hepatocellular carcinoma

收稿 2026-03-31 录用 2026-06-24 发表 2026-06-29

作者Xi Chen; Zhengwen Zhang; Siqian Cui; Yiguo Zhang

作者单位1. Chongqing University; 2. University College London; 3. Chongqing University Jiangjin Hospital

PDF源文件 DOI 网页

200 天

Transient receptor potential (TRP) channels: an emerging therapeutic target for the treatment of cardiac hypertrophy

收稿 2025-11-28 录用 2026-06-16 发表 2026-06-26

作者Saumya Upadhyay; Shyam Sunder Sharma

作者单位1. National Institute of Pharmaceutical Education and Research

PDF源文件 DOI 网页

139 天

The protective role of SIRT1 in cardiovascular disease: from molecular mechanisms to potential therapeutic strategies

收稿 2026-01-24 录用 2026-06-12 发表 2026-06-21

作者Haixin Ma; Shuya Wang; Zijian Dang; Wentao Xie; Ning Li; Jiayan Li; Yang Yang; Zhenxiao Jin

作者单位1. Northwest University; 2. The Fourth Military Medical University

PDF源文件 DOI 网页

Expert Matching · Case Demo

把投稿要求，转成可验证的期刊方案

说清专业、时限和作者背景，CrushSCI 结合真实审稿样本，给出拟题方向、期刊初筛与周期判断。

客户询问

我是环境工程专业，需要一篇 SCI，希望 3 个月内见刊。没有基金，也没有大牛挂名，可以投哪些期刊？

CrushSCI回复

可以。先按 90 天时限做可行性筛选，同步查找无基金、无知名作者挂靠的典型论文案例，作为选刊依据。重点核对研究质量与期刊 scope。

拟题建议: 《融合机器学习与生命周期评价的城市污水处理碳排放预测与优化》
数据库初筛: Environmental Technology & Innovation

样本口径2026 年最近 5 篇有效论文样本

平均审稿96.4 天

中位数77 天

EXPERT OPINION ON THERAPEUTIC TARGETS

全部论文审稿周期

5-FU in combination with PARP inhibitor ABT-888 deregulates MGMT-dependent mismatch repair (MMR) pathway in MMR-proficient colorectal cancer stem cells by modulating MGMT/PARP1/MSH6 complex

The evolving bioinformatic approaches to identifying genetic targets of promise in cancers

Tailored strategies to overcome third-generation TKI resistance in EGFR-mutated non-small cell lung cancer

APE1/Ref-1: multifunctional biology, selective inhibition, and the path to clinical translation

Fibroblast activation protein inhibitor-based theranostics in neuroendocrine neoplasms

Possibility to therapeutically exploit RGPR-p117 as a target in cancer cells

The role of bile acid receptors in cholestatic liver disease: pathophysiological insights and therapeutic advances

Molecular insights for targeting the Nrf1 pathway in hepatocellular carcinoma

Transient receptor potential (TRP) channels: an emerging therapeutic target for the treatment of cardiac hypertrophy

The protective role of SIRT1 in cardiovascular disease: from molecular mechanisms to potential therapeutic strategies

把投稿要求，转成可验证的期刊方案

联系 CrushSCI

扫码添加微信好友

正在维护

EXPERT OPINION ON THERAPEUTIC TARGETS

全部论文审稿周期

5-FU in combination with PARP inhibitor ABT-888 deregulates MGMT-dependent mismatch repair (MMR) pathway in MMR-proficient colorectal cancer stem cells by modulating MGMT/PARP1/MSH6 complex

The evolving bioinformatic approaches to identifying genetic targets of promise in cancers

Tailored strategies to overcome third-generation TKI resistance in EGFR-mutated non-small cell lung cancer

APE1/Ref-1: multifunctional biology, selective inhibition, and the path to clinical translation

Fibroblast activation protein inhibitor-based theranostics in neuroendocrine neoplasms

Possibility to therapeutically exploit RGPR-p117 as a target in cancer cells

The role of bile acid receptors in cholestatic liver disease: pathophysiological insights and therapeutic advances

Molecular insights for targeting the Nrf1 pathway in hepatocellular carcinoma

Transient receptor potential (TRP) channels: an emerging therapeutic target for the treatment of cardiac hypertrophy

The protective role of SIRT1 in cardiovascular disease: from molecular mechanisms to potential therapeutic strategies

相关榜单与期刊入口